MOLLIE ROBINSON: Open Payments
NPI 1104456656 · PICAYUNE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,263 in 277 payments from 28 companies in 2025. Trend: 2023 $0 · 2024 $1,554 · 2025 $6,263
Food & beverage: $6,253Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 98 | $1,431 |
| Janssen Biotech, Inc. | 28 | $663 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $442 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $415 |
| Madrigal Pharmaceuticals | 4 | $384 |
| Gilead Sciences, Inc. | 13 | $346 |
| Regeneron Healthcare Solutions, Inc. | 10 | $329 |
| Celltrion USA Inc. | 12 | $290 |
| Ipsen Biopharmaceuticals, Inc | 9 | $282 |
| Novo Nordisk Inc | 5 | $243 |
Products named: TREMFYA, RINVOQ, DUPIXENT, ENTYVIO, XIFAXAN, REZDIFFRA, SKYRIZI, LINZESS.
Industry payments across MS — which companies pay providers there.
